Medicago Inc.

Medicago Inc. was a Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as bioreactors to produce proteins, candidate vaccines, and medications. By using live plant leaves as hosts in the discovery and manufacturing process, the Medicago "Proficia" technology intended to create a rapid, high-yield system for its product candidates. Privately owned by a subsidiary of Mitsubishi Tanabe Pharma, Medicago and its product development programs were terminated by Mitsubishi in February 2023.

The main clinical targets for Medicago product candidates were antiviral vaccines and antibody therapeutics. The company's name was derived from the Latin word for alfalfa, which was the first plant the company used to develop its technologies. Medicago technologies evolved from research at the Laval University and Agriculture and Agri-Food Canada in the 1990s.